17,261 trials
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Dermatitis, Atopic Dermatitis
Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308
Pancreatic Cancer
Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants
Cirrhosis · Chronic Hepatitis C · Hepatitis C
Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants
Pulmonary Tuberculosis
Primary: The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment. — 0.133…
Non-small Cell Lung Cancer
Primary: 6-month Progression Free Survival Rate — 74 percentage of participants
Substance Use · Psychopathy
Primary: Percent Days Abstinent Per Month From Drug Use — 46.92; 55.16 percentage of days abstinent — p=.02
Other Obstetric Trauma - Delivered
Primary: Partecipant With Perineal Laceration — 3; 31 participants
Lymphocytic Leukemia
Primary: Clinical Response (Complete or Partial Remission) — 0; 1; 0; 3 participants
Adenocarcinoma of the Pancreas · Pancreatic Cancer · Recurrent Pancreatic Cancer
Primary: Objective Response (Complete and Partial) Evaluated Using RECIST Criteria — 0 participants
Fatty Liver Disease, Nonalcoholic
Primary: Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months — 5 units on a scale — p=0.015
Androgen-independent Prostate Cancer
Primary: Median Time to Progression (TTP) — 4.9; 6.6 Months
Migraine
Primary: Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day — 1.9; 17.0; 43.8; 52.7 nanomolar (nM)
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients